Business Wire

VA-SES

3.6.2021 08:52:10 CEST | Business Wire | Press release

Share
Isotropic Systems and SES GS Complete Milestone Trials to Unlock Next-Gen Connectivity for U.S. Military

SES Government Solutions (SES GS), a wholly-owned subsidiary of SES, and Isotropic Systems, a leading developer of transformational broadband terminal technologies, announce the successful completion of the first of two milestone next-generation antenna trials with the U.S. Military aimed at unleashing unprecedented information distribution to warfighters across the battlefield.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602006167/en/

The U.S. Air Force and U.S. Army, through the innovative Defense Experimentation Using Commercial Space Internet (DEUCSI) program, are evaluating the ability of Isotropic Systems’ optical beamforming antenna to enable frontline armed forces to access high-speed, real-time data simultaneously over multiple commercial and military satellites.

First phase dual-beam tests conducted at the Harwell Science, Technology and Innovation Campus near Oxford, UK, have successfully demonstrated transformational optics at the core of Isotropic Systems’ multi-beam terminal that are fully capable of linking with multiple satellites at the same time.

Over-the-air (OTA) trials conducted at an SES teleport in Port St. Lucie, Florida, also part of phase one, have verified the Isotropic Systems’ high-performance multi-beam platform meets military requirements to acquire and track SES’ O3b MEO satellites.

Phase two trials will test Isotropic Systems’ latest antenna prototype over links with SES satellites in geostationary orbit (GEO) and medium earth orbit (MEO), demonstrating seamless satellite-to-satellite transitions and a redundant, resilient leap in wartime communications.

The DEUCSI trials will wrap up in 2021, ahead of the commercial launch of Isotropic Systems’ optical multi-beam antenna production scheduled for 2022, and in time to support SES’ new high-throughput MEO constellation satellites coming online, the groundbreaking O3b mPOWER system.

“The armed forces and defense agencies are incredibly good at acquiring actionable information, but they run into bottlenecks when they try to distribute that mission-critical data over single beam parabolic antennas and other outdated infrastructure,” said Scott Sprague, Isotropic Systems CCO. “These milestone trials with the U.S. Army and Air Force are successfully demonstrating the multi-beam, multi-orbit connectivity and capabilities our high-performance terminals will put in the hands of frontline warfighters and decision makers across the government sector and battlespace.”

“Next-gen satellites and constellations need equally robust and resilient terminals and ground infrastructure to meet the government’s ’Fighting SATCOM’ vision,” said Pete Hoene, President and CEO of SES Government Solutions, Brigadier General, USAF (Ret.). “Interoperability and multi-orbit capabilities are essential to achieving this vision, and these collaborative trials with the armed forces demonstrate how Isotropic Systems’ multi-beam antenna can successfully deliver robust connectivity across our vast MEO and GEO fleet. Each successful phase is a prime example of how the government and commercial partners can develop capabilities in parallel, which is especially important to us as we ready to launch our O3b mPOWER constellation and SES-17 satellite this year.

“Without affecting the main communications link, the Isotropic Systems multi-beam terminal can use a second or third link to evaluate the environment to preemptively decide the best routing option at any given time to maximize performance,” explained Brian Billman, Vice President of Product Management for Isotropic Systems. “That’s the level of differentiating capabilities our terminal roadmap leads to as a result of these important trials with the U.S. military.”

For further information please contact:

About SES Government Solutions

SES Government Solutions (SES GS) is a wholly-owned subsidiary of SES, the leader in global content connectivity solutions. SES GS operates under a proxy board allowing them to provide services through contracts with the U.S. Government, including classified work. SES GS is exclusively focused on meeting the satellite communications needs of the U.S. Government. Leveraging more than four decades of experience in the government SATCOM market, SES GS offers robust and secure end-to-end satellite communications solutions. Further information can be found at www.ses-gs.com .

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .

About Isotropic Systems

Isotropic Systems is developing the world’s first multi-service, high-bandwidth, low power, fully integrated high throughput terminals designed to support the satellite industry to 'reach beyond' traditional markets and acquire new customers with a full suite of high throughput services. The company’s team of industry experts and scientists has pioneered several firsts in satellite terminal design resulting in a line of terminals that are customizable to meet the performance, cost and power requirements of countless applications – from the most complex government defense systems and mobile backhaul solutions capable of extending 5G, to next-gen connected experiences aboard commercial airliners, cruise ships, offshore rigs, and even small fishing boats at sea. Isotropic Systems’ Series A funding was led by Boeing to advance space-based connectivity. Further information is available at www.isotropicsystems.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/SES.Satellites/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release

£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release

Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye